Format

Send to

Choose Destination
Curr Opin Urol. 2018 Mar;28(2):197-204. doi: 10.1097/MOU.0000000000000486.

Prostate-specific membrane antigen theranostics: therapy with lutetium-177.

Author information

1
Department of Nuclear Medicine, University Hospital Bonn, Bonn, Germany.
2
Department of Radiation Oncology.
3
Department of Medical Oncology.
4
Sir Peter MacCallum Department of Oncology.
5
Department of Cancer Imaging, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia.

Abstract

PURPOSE OF REVIEW:

Prostate-specific membrane antigen (PSMA) theranostics offers a new approach for a personalized and targeted treatment for metastatic prostate cancer. Lutetium-177-labelled PSMA-ligands (Lu-PSMA) is a radionuclide therapy that is directed to PSMA expressing prostate cancer. Clinical experience with Lu-PSMA in men with advanced prostate cancer is growing. The purpose of this review is to outline the mechanism of action of this therapy, summarize recent efficacy and toxicity data and highlight future direction and challenges in establishing Lu-PSMA treatment as part of routine clinical practice.

RECENT FINDINGS:

The first reports on safety and efficacy of Lu-PSMA have been retrospective series of men with advanced prostate cancer who previously failed conventional therapies and received Lu-PSMA on compassionate basis. These studies highlight promising efficacy, favourable toxicity profile and quality of life improvements. Limitation stem from the retroospective nature of these data with short follow-up.

SUMMARY:

Several studies suggest that radionuclide therapy with Lu-PSMA has high activity and is well tolerated. Crucial to establishing this treatment in routine clinical management will be the generation of high-level evidence from prospective trials that can confirm the encouraging patient outcomes reported to date.

Supplemental Content

Full text links

Icon for Wolters Kluwer
Loading ...
Support Center